FDA Clearance Tracker · P180050-S006
Barostim System
Last checked: Nov 20, 2026Latest source record: Jun 14, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Jun 14, 2022
Approved
Time to decision
25 days
Received May 20, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P180050-S006
- Device name
- Barostim System
- Applicant
- Cvrx, Inc.
- Applicant location
- Minneapolis, MN
- Received
- May 20, 2022
- Decided
- Jun 14, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P180050
Device type
- Device type
- Stimulator, carotid sinus nerve (DSR)
- Device class
- Class III
- Regulation
- 21 CFR 870.3850
FDA's approval statement
As written in FDA's record.
Approval for the revised statistical analysis plan.
Source documents
Other decisions for Cvrx, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- BAROSTIM NEO® SystemBreakthroughPMA
P180050 · Decided Aug 16, 2019 · 239 days after receipt
Device type: Stimulator, carotid sinus nerve (DSR) · Cardiology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.